Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]

Group 1: Project Status and Orders - The Huaxi Proton Medical Project's equipment has completed factory production, but installation cannot begin until site conditions are met, making year-end acceptance unlikely [2] - The company has not received new orders for proton therapy equipment in the last two years due to long preparation times for funding and construction, despite some hospitals obtaining configuration permits [2] - The company has completed technical breakthroughs and design for a miniaturized proton therapy system [2] Group 2: Product Development and Revenue - The isotope main equipment arrived at the production base in June 2025, with production planned for 2026 [3] - The company’s subsidiary is developing a special plastic product (Peek) for various industries, but it has not yet generated revenue [3] - The company’s revenue from the nuclear power sector is less than 10% [3] Group 3: Financial Performance and Strategies - The company aims to achieve profitability by reducing costs, enhancing strategic customer collaboration, and upgrading products based on market needs [3] - The company has faced significant losses for several years but is not currently at risk of being delisted according to stock exchange rules [4] - The company is focused on improving operational performance and enhancing investor relations to align intrinsic value with market value [4] Group 4: Corporate Governance and Future Plans - The company is not considering a private placement to increase shareholding ratios at this time [4] - The company is committed to completing its asset disposal work by the end of 2025 [4] - The company is actively embracing artificial intelligence to drive high-end, green, and intelligent transformation [5]